Gain Therapeutics Q3 Loss Narrows

(RTTNews) - Gain Therapeutics, Inc. (GANX) on Tuesday reported a narrower net loss for the third quarter of 2026 compared with the same period in 2025, as reduced research and development and general and administrative expenses lowered overall operating costs.

The company posted a net loss of $3.16 million, or $0.07 per share, compared with a net loss of $5.28 million, or $0.15 per share, a year earlier. Total operating expenses declined to $3.20 million from $4.79 million.

For the first nine months of 2026, Gain Therapeutics reported a net loss of $13.44 million, or $0.31 per share, compared with a net loss of $15.62 million, or $0.50 per share, in the prior-year period. Total operating expenses decreased to $13.24 million from $14.24 million.

GANX is currently trading at $1.0500, down $0.0400 or 3.67 percent on the Nasdaq.